Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation

Zhimin Gu, Yuxuan Liu, Feng Cai, McKenzie Patrick, Jakub Zmajkovic, Hui Cao, Yuannyu Zhang, Alpaslan Tasdogan, Mingyi Chen, Le Qi, Xin Liu, Kailong Li, Junhua Lyu, Kathryn E. Dickerson, Weina Chen, Min Ni, Matthew E. Merritt, Sean J. Morrison, Radek C. Skoda, Ralph J. DeBerardinisJian Xu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Epigenetic gene regulation and metabolism are highly intertwined, yet little is known about whether altered epigenetics influence cellular metabolism during cancer progression. Here, we show that EZH2 and NRASG12D mutations cooperatively induce progression of myeloproliferative neoplasms to highly penetrant, transplantable, and lethal myeloid leukemias in mice. EZH1, an EZH2 homolog, is indispensable for EZH2-deficient leukemia-initiating cells and constitutes an epigenetic vulnerability. BCAT1, which catalyzes the reversible transamination of branched-chain amino acids (BCAA), is repressed by EZH2 in normal hematopoiesis and aberrantly activated in EZH2-deficient myeloid neoplasms in mice and humans. BCAT1 reactivation cooperates with NRASG12D to sustain intracellular BCAA pools, resulting in enhanced mTOR signaling in EZH2-deficient leukemia cells. Genetic and pharmacologic inhibition of BCAT1 selectively impairs EZH2-deficient leukemia-initiating cells and constitutes a metabolic vulnerability. Hence, epigenetic alterations rewire intracellular metabolism during leukemic transformation, causing epigenetic and metabolic vulnerabilities in cancer-initiating cells. SIGNIFICANCE: EZH2 inactivation and oncogenic NRAS cooperate to induce leukemic transformation of myeloproliferative neoplasms by activating BCAT1 to enhance BCAA metabolism and mTOR signaling. We uncover a mechanism by which epigenetic alterations rewire metabolism during cancer progression, causing epigenetic and metabolic liabilities in cancer-initiating cells that may be exploited as potential therapeutics.See related commentary by Li and Melnick, p. 1158.This article is highlighted in the In This Issue feature, p. 1143.

Original languageEnglish (US)
Pages (from-to)1228-1247
Number of pages20
JournalCancer discovery
Volume9
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Branched Chain Amino Acids
Epigenomics
Neoplasms
Leukemia
Myeloid Leukemia
Hematopoiesis
Mutation
Genes

ASJC Scopus subject areas

  • Oncology

Cite this

Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation. / Gu, Zhimin; Liu, Yuxuan; Cai, Feng; Patrick, McKenzie; Zmajkovic, Jakub; Cao, Hui; Zhang, Yuannyu; Tasdogan, Alpaslan; Chen, Mingyi; Qi, Le; Liu, Xin; Li, Kailong; Lyu, Junhua; Dickerson, Kathryn E.; Chen, Weina; Ni, Min; Merritt, Matthew E.; Morrison, Sean J.; Skoda, Radek C.; DeBerardinis, Ralph J.; Xu, Jian.

In: Cancer discovery, Vol. 9, No. 9, 01.09.2019, p. 1228-1247.

Research output: Contribution to journalArticle

Gu, Z, Liu, Y, Cai, F, Patrick, M, Zmajkovic, J, Cao, H, Zhang, Y, Tasdogan, A, Chen, M, Qi, L, Liu, X, Li, K, Lyu, J, Dickerson, KE, Chen, W, Ni, M, Merritt, ME, Morrison, SJ, Skoda, RC, DeBerardinis, RJ & Xu, J 2019, 'Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation', Cancer discovery, vol. 9, no. 9, pp. 1228-1247. https://doi.org/10.1158/2159-8290.CD-19-0152
Gu Z, Liu Y, Cai F, Patrick M, Zmajkovic J, Cao H et al. Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation. Cancer discovery. 2019 Sep 1;9(9):1228-1247. https://doi.org/10.1158/2159-8290.CD-19-0152
Gu, Zhimin ; Liu, Yuxuan ; Cai, Feng ; Patrick, McKenzie ; Zmajkovic, Jakub ; Cao, Hui ; Zhang, Yuannyu ; Tasdogan, Alpaslan ; Chen, Mingyi ; Qi, Le ; Liu, Xin ; Li, Kailong ; Lyu, Junhua ; Dickerson, Kathryn E. ; Chen, Weina ; Ni, Min ; Merritt, Matthew E. ; Morrison, Sean J. ; Skoda, Radek C. ; DeBerardinis, Ralph J. ; Xu, Jian. / Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation. In: Cancer discovery. 2019 ; Vol. 9, No. 9. pp. 1228-1247.
@article{af13809e67a1413d8e477fd8729eb315,
title = "Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation",
abstract = "Epigenetic gene regulation and metabolism are highly intertwined, yet little is known about whether altered epigenetics influence cellular metabolism during cancer progression. Here, we show that EZH2 and NRASG12D mutations cooperatively induce progression of myeloproliferative neoplasms to highly penetrant, transplantable, and lethal myeloid leukemias in mice. EZH1, an EZH2 homolog, is indispensable for EZH2-deficient leukemia-initiating cells and constitutes an epigenetic vulnerability. BCAT1, which catalyzes the reversible transamination of branched-chain amino acids (BCAA), is repressed by EZH2 in normal hematopoiesis and aberrantly activated in EZH2-deficient myeloid neoplasms in mice and humans. BCAT1 reactivation cooperates with NRASG12D to sustain intracellular BCAA pools, resulting in enhanced mTOR signaling in EZH2-deficient leukemia cells. Genetic and pharmacologic inhibition of BCAT1 selectively impairs EZH2-deficient leukemia-initiating cells and constitutes a metabolic vulnerability. Hence, epigenetic alterations rewire intracellular metabolism during leukemic transformation, causing epigenetic and metabolic vulnerabilities in cancer-initiating cells. SIGNIFICANCE: EZH2 inactivation and oncogenic NRAS cooperate to induce leukemic transformation of myeloproliferative neoplasms by activating BCAT1 to enhance BCAA metabolism and mTOR signaling. We uncover a mechanism by which epigenetic alterations rewire metabolism during cancer progression, causing epigenetic and metabolic liabilities in cancer-initiating cells that may be exploited as potential therapeutics.See related commentary by Li and Melnick, p. 1158.This article is highlighted in the In This Issue feature, p. 1143.",
author = "Zhimin Gu and Yuxuan Liu and Feng Cai and McKenzie Patrick and Jakub Zmajkovic and Hui Cao and Yuannyu Zhang and Alpaslan Tasdogan and Mingyi Chen and Le Qi and Xin Liu and Kailong Li and Junhua Lyu and Dickerson, {Kathryn E.} and Weina Chen and Min Ni and Merritt, {Matthew E.} and Morrison, {Sean J.} and Skoda, {Radek C.} and DeBerardinis, {Ralph J.} and Jian Xu",
year = "2019",
month = "9",
day = "1",
doi = "10.1158/2159-8290.CD-19-0152",
language = "English (US)",
volume = "9",
pages = "1228--1247",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation

AU - Gu, Zhimin

AU - Liu, Yuxuan

AU - Cai, Feng

AU - Patrick, McKenzie

AU - Zmajkovic, Jakub

AU - Cao, Hui

AU - Zhang, Yuannyu

AU - Tasdogan, Alpaslan

AU - Chen, Mingyi

AU - Qi, Le

AU - Liu, Xin

AU - Li, Kailong

AU - Lyu, Junhua

AU - Dickerson, Kathryn E.

AU - Chen, Weina

AU - Ni, Min

AU - Merritt, Matthew E.

AU - Morrison, Sean J.

AU - Skoda, Radek C.

AU - DeBerardinis, Ralph J.

AU - Xu, Jian

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Epigenetic gene regulation and metabolism are highly intertwined, yet little is known about whether altered epigenetics influence cellular metabolism during cancer progression. Here, we show that EZH2 and NRASG12D mutations cooperatively induce progression of myeloproliferative neoplasms to highly penetrant, transplantable, and lethal myeloid leukemias in mice. EZH1, an EZH2 homolog, is indispensable for EZH2-deficient leukemia-initiating cells and constitutes an epigenetic vulnerability. BCAT1, which catalyzes the reversible transamination of branched-chain amino acids (BCAA), is repressed by EZH2 in normal hematopoiesis and aberrantly activated in EZH2-deficient myeloid neoplasms in mice and humans. BCAT1 reactivation cooperates with NRASG12D to sustain intracellular BCAA pools, resulting in enhanced mTOR signaling in EZH2-deficient leukemia cells. Genetic and pharmacologic inhibition of BCAT1 selectively impairs EZH2-deficient leukemia-initiating cells and constitutes a metabolic vulnerability. Hence, epigenetic alterations rewire intracellular metabolism during leukemic transformation, causing epigenetic and metabolic vulnerabilities in cancer-initiating cells. SIGNIFICANCE: EZH2 inactivation and oncogenic NRAS cooperate to induce leukemic transformation of myeloproliferative neoplasms by activating BCAT1 to enhance BCAA metabolism and mTOR signaling. We uncover a mechanism by which epigenetic alterations rewire metabolism during cancer progression, causing epigenetic and metabolic liabilities in cancer-initiating cells that may be exploited as potential therapeutics.See related commentary by Li and Melnick, p. 1158.This article is highlighted in the In This Issue feature, p. 1143.

AB - Epigenetic gene regulation and metabolism are highly intertwined, yet little is known about whether altered epigenetics influence cellular metabolism during cancer progression. Here, we show that EZH2 and NRASG12D mutations cooperatively induce progression of myeloproliferative neoplasms to highly penetrant, transplantable, and lethal myeloid leukemias in mice. EZH1, an EZH2 homolog, is indispensable for EZH2-deficient leukemia-initiating cells and constitutes an epigenetic vulnerability. BCAT1, which catalyzes the reversible transamination of branched-chain amino acids (BCAA), is repressed by EZH2 in normal hematopoiesis and aberrantly activated in EZH2-deficient myeloid neoplasms in mice and humans. BCAT1 reactivation cooperates with NRASG12D to sustain intracellular BCAA pools, resulting in enhanced mTOR signaling in EZH2-deficient leukemia cells. Genetic and pharmacologic inhibition of BCAT1 selectively impairs EZH2-deficient leukemia-initiating cells and constitutes a metabolic vulnerability. Hence, epigenetic alterations rewire intracellular metabolism during leukemic transformation, causing epigenetic and metabolic vulnerabilities in cancer-initiating cells. SIGNIFICANCE: EZH2 inactivation and oncogenic NRAS cooperate to induce leukemic transformation of myeloproliferative neoplasms by activating BCAT1 to enhance BCAA metabolism and mTOR signaling. We uncover a mechanism by which epigenetic alterations rewire metabolism during cancer progression, causing epigenetic and metabolic liabilities in cancer-initiating cells that may be exploited as potential therapeutics.See related commentary by Li and Melnick, p. 1158.This article is highlighted in the In This Issue feature, p. 1143.

UR - http://www.scopus.com/inward/record.url?scp=85071786991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071786991&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-19-0152

DO - 10.1158/2159-8290.CD-19-0152

M3 - Article

C2 - 31189531

AN - SCOPUS:85071786991

VL - 9

SP - 1228

EP - 1247

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 9

ER -